Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v3-FR Version v1-EN
Language French English
Date Updated 2023-08-16 2018-09-17
Drug Identification Number 02273225 02273225
Brand name ENABLEX ENABLEX
Common or Proper name darifenacin hydrobromide darifenacin hydrobromide
Company Name SEARCHLIGHT PHARMA INC SEARCHLIGHT PHARMA INC
Ingredients DARIFENACIN DARIFENACIN
Strength(s) 15MG 15MG
Dosage form(s) TABLET (EXTENDED-RELEASE) TABLET (EXTENDED-RELEASE)
Route of administration ORAL ORAL
Packaging size Bottles of 100 Bottles of 100
ATC code G04BD G04BD
ATC description OTHER UROLOGICALS, INCL ANTISPASMODICS OTHER UROLOGICALS, INCL ANTISPASMODICS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date
Actual start date 2018-09-17 2018-09-17
Estimated end date 2018-11-15 2018-11-15
Actual end date 2018-11-15
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments Reason for Shortage: Production Delay For more information, please contact Methapharm Inc. at 1-800-287-7686, sales@methapharm.com or by fax at 1-519-751-9149. Reason for Shortage: Production Delay For more information, please contact Methapharm Inc. at 1-800-287-7686, sales@methapharm.com or by fax at 1-519-751-9149.
Health Canada comments